QBS72S
Cancer (with potential for brain tumors/metastases)
Pre-clinicalActive
Key Facts
Indication
Cancer (with potential for brain tumors/metastases)
Phase
Pre-clinical
Status
Active
Company
About Quadriga BioSciences
Quadriga BioSciences is a private, preclinical-stage biotech advancing a novel oncology therapeutic platform. Its core technology leverages the L-type Amino Acid Transporter 1 (LAT1) to selectively deliver cytotoxic payloads into rapidly proliferating cancer cells and across the blood-brain barrier, addressing a key challenge in treating brain cancers and other solid tumors. The company is singularly focused on developing its lead candidate, QBS72S, a DNA interstrand cross-linking agent. Quadriga appears to be in a capital-efficient, asset-centric development phase, seeking partnerships to advance its program.
View full company profile